MTOR and breast cancer: In this context, we report here the results of in vitro and in vivo investigation to test the utility of 111In-bevacizumab in the detection of the response to the anti-angiogenic mTOR inhibitor rapamycin, analogues of which (everolimus) are used to treat renal and breast cancer.